Anti-SARS-CoV S glycoprotein [4D4]

Absolute Antibody

Anti-SARS-CoV S glycoprotein [4D4]

9

This antibody specifically binds the amino acids 318-510 in the S1 domain of the SARS-CoV Spike protein (Urbani strain).

This antibody inhibits the association of SARS-CoV s protein to the angiotensin-converting enzyme 2 (ACE2) receptor by binding to specific amino acids on the S1 domain of the spike protein of the virus. The originally characterized antibody had a neutralizing titer 200TCID50 of 12.5 microg/ml (Coughlin et at.,2006). When incubated with S12-510- Fc recombinant protein it failed to block the interaction of this protein with the cellular receptor but inhibited a post-binding event and prevented viral entry. Combination of this antibody with another antibody 5D3, that binds to a different epitope resulted in increased inhibition of virus. The ability of mAb 4D4 to more efficiently inhibit viral entry when added post virus binding suggests that the S protein might undergo a conformational change following binding to ACE2 leading to unmasking of the epitope recognized by the 4D4 antibody. Simultaneously, 4D4 was also used in a standardentry inhibition assay as a positive control for determining the degree of inhibition of pseudotyped virus entry. (Coughlin et at.,2009). This antibody 4D4 showed about 50% binding to Sin845 S1 protein relative to their binding to Urbani S1 protein. GZ0402-S1 protein showed minimal of 57% binding to HmAbs 4D4 (Elshabrawy et al., 2012). Other applications include ELISA.

ELISA, Neutralisation/Blocking

Research Use Only

Monoclonal

4D4

Human

IgM

Spike glycoprotein

This reformatted human antibody was made using the variable domain sequences of the original Human IgG2 format, for improved compatibility with existing reagents, assays and techniques.

Virus

-20°C,2°C to 8°C

12352203